MBI Med Biogene Inc

Med BioGene Inc. (TSX VENTURE:MBI) today announced the publication in the
Journal of Thoracic Oncology of data demonstrating a second, independent
validation of the 15-gene signature to be marketed as GeneFx(R) Lung entitled
"Validation of a Histology-Independent Prognostic Gene Signature for
Early-Stage, Non-Small-Cell Lung Cancer Including Stage IA Patients." The study
validated in a prospective and blinded manner the prognostic accuracy of the
GeneFx Lung signature in an independent cohort of 181 early-stage (I and II)
non-small-cell lung cancer (NSCLC) tumor specimens in different histologic
subtypes. 


GeneFx Lung is a proprietary gene expression-based test to improve upon staging
for identifying those patients with early-stage NSCLC who, following surgical
removal of their tumor, are at higher and lower risks of mortality. In an
initial study published in the Journal of Clinical Oncology of patient specimens
from the National Cancer Institute of Canada Clinical Trials Group JBR.10 trial,
patients classified by GeneFx Lung as high risk benefited from adjuvant
chemotherapy, and those classified as low risk did not benefit and may have
experienced a detrimental effect from adjuvant chemotherapy. GeneFx Lung was
subsequently validated in predicting patient mortality in four independent
studies involving data from tumor specimens totaling 676 untreated early-stage
NSCLC patients. 


On April 15, 2011, MBI and Precision Therapeutics Inc. entered into a
commercialization, license and research reimbursement agreement which provides
to Precision exclusive global rights to develop and commercialize GeneFx Lung.  


"We believe that the blinded, prospective validation results published in the
Journal of Thoracic Oncology, along with the prior validation results published
in the Journal of Clinical Oncology, establish that the use of GeneFx Lung will
result in better-informed and more personalized treatment decisions and improve
the selection of patients who may benefit from adjuvant chemotherapy", stated
Erinn B. Broshko, Executive Chairman of MBI. 


The study published in the Journal of Thoracic Oncology was led by Drs.
Ming-Sound Tsao, Frances A. Shepherd and Sandy D. Der at the Princess Margaret
Cancer Centre, University Health Network in Toronto, and included Dr. Igor
Jurisica, Jenna Sykes, Melania Pintilie, Dr. Chang-Qi Zhu, Dr. Dan Strumpf and
Ni Liu.


The publication in the Journal of Thoracic Oncology can be assessed online
(http://journals.lww.com/jto/Abstract/2014/01000/Validation_of_a_Histology_Independent_Prognostic.9.aspx).
 


The initial publication in the Journal of Clinical Oncology can also be assessed
online
(http://jco.ascopubs.org/content/early/2010/09/07/JCO.2009.26.4325.abstract) as
can the independent editorial
(http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2010.31.0144) from Drs. Yang Xie
and John D. Minna of the Hamon Center for Therapeutic Oncology Research and
Simmons Cancer Center, University of Texas Southwestern Medical Center.


About Precision Therapeutics

Precision Therapeutics, a leading life science company based in Pittsburgh,
Pennsylvania, is dedicated to improving the outcomes of cancer patients by
providing personalized medicine solutions that aim to increase quality of life
and cancer survival rates. Precision offers a portfolio of products developed to
help guide physicians and patients with difficult clinical decisions throughout
the continuum of cancer care. 


Precision currently markets a number of tests through its CLIA-certified
laboratory, including ChemoFx(R), BioSpeciFx(R) and GeneFx(R) Colon. 


For more information on Precision, please visit www.precisiontherapeutics.com. 

About Med BioGene

MBI is a life science company based in Vancouver, British Columbia that is
currently focused on managing the license and rights to GeneFx Lung. MBI's
common shares are listed for trading on the TSX Venture Exchange.  


For more information on MBI, please visit www.medbiogene.com. 

The TSX Venture Exchange does not accept responsibility for the adequacy or
accuracy of this release.


Certain statements in this press release contain forward-looking statements and
information ("forward-looking statements") under applicable United States and
Canadian securities legislation. Words such as "anticipates," "believes,"
"estimates," "expects," "intends," "may," "plans," "projects," "will," "would"
and similar expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these identifying words.
Forward looking statements include, but are not limited to, that with respect to
the timing, completion and/or results of clinical trials or studies, the timing
for commercialization of any products, future profits, future product revenues,
future shareholder value, future operations and plans, the completion and use of
proceeds from transactions or financings and the prospects for negotiating
partnerships or collaborations and their timing. These forward-looking
statements are only a prediction based upon the party's current expectations,
and actual events or results may differ materially. A party may not actually
achieve the plans, intentions or expectations disclosed in its forward-looking
statements. Forward-looking statements are subject to known and unknown risks
and uncertainties and are based on uncertain assumptions that could cause a
party's actual results and the timing of events to differ materially from those
anticipated in such forward-looking information. You are cautioned not to place
undue reliance on these forward-looking statements, which speak only as of the
date of this press release. A party's forward-looking statements do not reflect
the potential impact of any future partnerships, collaborations, acquisitions,
mergers, dispositions, joint ventures or investments that that party may make.
All forward-looking statements are qualified in their entirety by this
cautionary statement and a party undertakes no obligation to revise or update
any forward-looking statements as a result of new information, future events or
otherwise after the date of this press release, other than as required by
applicable law. Certain information included in this press release in respect of
Precision and its scientific, clinical and/ or commercialization efforts have
been provided to MBI by Precision. MBI may not have been able to confirm the
accuracy of such information and you should not place undue reliance on any such
information, including any information regarding Precision that would constitute
forward-looking information. A redacted copy of the commercialization agreement,
as amended, between Precision and MBI may be found at www.sedar.com. Each
trademark, trade name or service mark of any entity appearing in this news
release belongs to its holder.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Med BioGene Inc.
Erinn B. Broshko
Executive Chairman
(800) 641-3593
ebroshko@medbiogene.com
www.medbiogene.com

Med Biogene (TSXV:MBI)
Historical Stock Chart
From Apr 2024 to May 2024

Med Biogene (TSXV:MBI)
Historical Stock Chart
From May 2023 to May 2024